Rocket Pharmaceuticals, Inc.
RCKTNASDAQHealthcare● Active
$2.70
$-0.05(-1.82%)
Market Cap$294822582
P/E Ratio—
52W High$5.45
52W Low$2.4
Rocket Pharmaceuticals, Inc. (RCKT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RCKT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.01B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.14B | $0.17B | $0.19B | $0.17B | $0.13B |
| G&A Expenses | $0.09B | $0.10B | $0.07B | $0.06B | $0.04B |
| Total Operating Expenses | $0.22B | $0.27B | $0.26B | $0.22B | $0.17B |
| Operating Income | ($0.23B) | ($0.27B) | ($0.26B) | ($0.22B) | ($0.17B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.02B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| Income Before Tax | ($0.22B) | ($0.26B) | ($0.25B) | ($0.22B) | ($0.17B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.22B) | ($0.26B) | ($0.25B) | ($0.22B) | ($0.17B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.68 |
| Wtd Avg Shares | 0.11B | 0.09B | 0.08B | 0.07B | 0.06B |
| EBITDA | ($0.21B) | ($0.25B) | ($0.24B) | ($0.21B) | ($0.16B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Rocket Pharmaceuticals, Inc. data
About Rocket Pharmaceuticals, Inc. (RCKT) Income Statement
Rocket Pharmaceuticals, Inc. (RCKT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RCKT reported revenue of $0.00B, gross profit of ($0.01B) (gross margin —), and net income of ($0.22B) — a net profit margin of —.
Frequently asked questions
RCKT · 4 questionsRocket Pharmaceuticals, Inc. (RCKT) reported revenue of $0.00B for 2025, down —% year-over-year.
RCKT revenueRCKT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08